Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden
{{output}}
In patients with metastasized, castration resistant prostate cancer (mCRPC) treatment with radium-223 (Xofigo) is an attractive therapeutic option. In particular, patients with high tumour load seem to profit from this treatment in regard of survival and quali... ...
